346 749

Cited 0 times in

시멘트 보강술을 시행한 골다공증성 척추 골절 환자에서 리세드로네이트, 알렌드로네이트와 칼슘 카보네이트 약물치료 후 발생하는 척추 골절의 비교 연구

DC Field Value Language
dc.contributor.author김진영-
dc.contributor.author김학선-
dc.contributor.author문성환-
dc.contributor.author문은수-
dc.contributor.author박진오-
dc.contributor.author이환모-
dc.date.accessioned2015-04-24T16:52:31Z-
dc.date.available2015-04-24T16:52:31Z-
dc.date.issued2009-
dc.identifier.issn1226-2102-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/104338-
dc.description.abstractPurpose: To evaluate the rate of new fractures of the spine after risedronate, alendronate or calcium carbonate in patients who had vertebroplasty or kyphoplasty due to compression fracture. Materials and Methods: We studied 292 patients with osteoporotic compression fractures who had received vertebroplasty or kyophoplasty between June 2003 and October 2007. Of these, 199 were evaluated for new fractures of the spine after treatment with risedronate, alendronate or calcium carbonate. Patients (n=199) were assigned to 1 of 4 groups: No treatment (n=71), risendronate (n=64), alendronate (n=42) or calcium carbonate group (n=22). Results: New fractures of the spine were morphogenically found in 19 patients (26.8%) in the no treatment group, in 11 (17.2%) in the risendronate group, in 8 (19.1 %) in the alendronate group, in 5 (22.8%) in the calcium carbonate group. Symptomatically, they were found in 6 patients (8.5%) in the no treatment group, in 4 (6.3%) in the risendronate group, in 3 patients (7.1 %) in the alendronate group, and in 2 patients (9.1 %) in the calcium carbonate group. Conclusion: At one year follow up none of the differences between groups in new fracture rates of the spine were statistically significant.-
dc.description.statementOfResponsibilityopen-
dc.format.extent436~441-
dc.relation.isPartOfJournal of the Korean Orthopaedic Association (대한정형외과학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.title시멘트 보강술을 시행한 골다공증성 척추 골절 환자에서 리세드로네이트, 알렌드로네이트와 칼슘 카보네이트 약물치료 후 발생하는 척추 골절의 비교 연구-
dc.title.alternativePrevention of New Vertebral Fractures after Treatment with Risedronate, Alendronate or Calcium Carbonate in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Orthopedic Surgery (정형외과학)-
dc.contributor.googleauthor김진영-
dc.contributor.googleauthor문은수-
dc.contributor.googleauthor이환모-
dc.contributor.googleauthor문성환-
dc.contributor.googleauthor박진오-
dc.contributor.googleauthor형지호-
dc.contributor.googleauthor김학선-
dc.identifier.doi10.4055/jkoa.2009.44.4.436-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01024-
dc.contributor.localIdA01093-
dc.contributor.localIdA01365-
dc.contributor.localIdA01372-
dc.contributor.localIdA01703-
dc.contributor.localIdA03333-
dc.relation.journalcodeJ01839-
dc.subject.keywordOsteoporosis-
dc.subject.keywordCompression fracture-
dc.subject.keywordRisedronate-
dc.subject.keywordAlendronate-
dc.subject.keywordCalcium carbonate-
dc.contributor.alternativeNameKim, Jin Young-
dc.contributor.alternativeNameKim, Hak Sun-
dc.contributor.alternativeNameMoon, Seong Hwan-
dc.contributor.alternativeNameMoon, Eun Su-
dc.contributor.alternativeNamePark, Jin Oh-
dc.contributor.alternativeNameLee, Hwan Mo-
dc.contributor.affiliatedAuthorKim, Jin Young-
dc.contributor.affiliatedAuthorKim, Hak Sun-
dc.contributor.affiliatedAuthorMoon, Seong Hwan-
dc.contributor.affiliatedAuthorMoon, Eun Su-
dc.contributor.affiliatedAuthorPark, Jin Oh-
dc.contributor.affiliatedAuthorLee, Hwan Mo-
dc.citation.volume44-
dc.citation.number4-
dc.citation.startPage436-
dc.citation.endPage441-
dc.identifier.bibliographicCitationJournal of the Korean Orthopaedic Association (대한정형외과학회지), Vol.44(4) : 436-441, 2009-
dc.identifier.rimsid52604-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.